BN SINA Pharmaceutical Industry PLC
DDSE:IBNSINA302.20
BDT
+1.00
(+0.33%)
ISIN
BD0464IBNSN2
Return %
Stock
S&P 500
1Y
3.21
14.20
3Y
5.44
81.12
5Y
11.27
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- A. K. M. Sadrul Islam
- Full Time Employees
- 5,200
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Dhaka Bangladesh
- IPO Date
- Nov 25, 2007
- Website
- ibnsinapharma.com
- Similar Companies
- Business
- The Ibn Sina Pharmaceutical Industry PLC is a Bangladesh-based healthcare and pharmaceutical manufacturing enterprise engaged in the development, manufacturing, marketing, and distribution of generic finished pharmaceutical formulations, natural medicines, active pharmaceutical ingredients, and pharmaceutical-grade packaging. Founded in 1983 and headquartered in Dhaka, Bangladesh, the company operates under three main business segments: Pharmaceuticals, Natural Medicine, and Allied Industrial Operations. The company serves domestic healthcare providers, retail pharmacies, hospital networks, government health institutions, and international export markets across Asia, Africa, and the Middle East. The company offers an extensive portfolio of over 500 commercial dosage forms across diverse therapeutic categories and drug delivery platforms. Its core product portfolio comprises solid oral dosage forms, including conventional tablets, enteric-coated tablets, sustained-release tablets, and hard gelatin capsules; liquid oral preparations, including oral suspensions, syrups, pediatric drops, and dry syrups for reconstitution; sterile injectable formulations, including liquid ampoules, liquid vials, and lyophilized powders; sterile ophthalmic and otic formulations, including eye drops, eye ointments, and ear drops; topical dermatological preparations, including therapeutic creams, ointments, lotions, and gels; and powdered sachets and effervescent granules. Therapeutic areas covered include cardiovascular agents such as antihypertensives and statins; gastrointestinal medications such as proton pump inhibitors and antacid suspensions; oral antidiabetics; anti-infectives, including broad-spectrum antibiotics, cephalosporins, antivirals, and antifungals; respiratory medicines, including bronchodilators, antihistamines, and anti-asthmatics; central nervous system and pain management drugs, including analgesics, non-steroidal anti-inflammatory drugs, and neurotropic vitamin complexes; and natural and Unani consumer health formulations, such as botanical remedies and dietary supplements. Notable commercial brand names include Gavisol, Dexlan, Xorel, Linax, Neuralgin, and Olmedip. Through its subsidiaries, the company also manufactures synthetic active pharmaceutical ingredients and plastic packaging supplies, including PET bottles, dropper bottles, and compression-molded closures. The company operates multiple subsidiaries to advance horizontal and vertical supply chain integration, including The IBN SINA Natural Medicine Ltd. (99.9% equity stake), dedicated to herbal and Unani pharmaceuticals; The IBN SINA API Industry Ltd. (99.9% equity stake), established for synthetic bulk active pharmaceutical ingredient synthesis; and The IBN SINA Polymer Industry Ltd. (65.0% equity stake), which provides specialized polymer containers and packaging components. In recent strategic developments, The Ibn Sina Pharmaceutical Industry PLC has undertaken major capital expenditure and infrastructure expansions to scale manufacturing capacity, enhance high-potency drug capabilities, and deepen backward integration. The company is advancing construction on its Unit-2 manufacturing facility located on a 15-acre site in Mawna, Gazipur (the Godhulia Project), a major multi-billion taka development designed to house dedicated lines for advanced oral solids, sterile injectables, and dedicated oncology drug formulations scheduled for completion by 2026. The company also commenced trial manufacturing operations at its Active Pharmaceutical Ingredient production plant located within the API Industrial Park in Gazaria, Munshiganj, significantly lowering reliance on imported raw materials. Additionally, the company expanded its polymer packaging unit to internalize component supply, authorized the acquisition of commercial land in the Feni District to support regional logistics and future manufacturing expansion, and maintained robust capital distribution policies through high cash dividend declarations.